Oppenheimer analyst Jeff Jones assigned a Buy rating to Chemomab Therapeutics (CMMB) today and set a price target of $42.00.
The post Oppenheimer Thinks Chemomab Therapeutics Stock is Going to Recover appeared first on Smarter Analyst.
Oppenheimer analyst Jeff Jones assigned a Buy rating to Chemomab...

https://www.smarteranalyst.com/new-blurbs/oppenheimer-thinks-chemomab-therapeutics-stock-is-going-to-recover/

#SmarterAnalyst